← All trials
NCT03189017
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 4, 2017
- Primary completion
- Oct 10, 2017
- Completion date
- Oct 24, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Beijing InnoCare Pharma Tech Co., Ltd.Lead sponsor
- IDT Australia Ltd.Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.